Deziglipel

Deziglipel
Clinical data
Other namesMKP10241; MKP-10241
Routes of
administration		Oral
Drug classGPR119 agonist; Antihyperglycemic agent
Identifiers
  • 2-[(1S)-1-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]ethoxy]-6-(2-fluoro-4-methylsulfonylphenyl)imidazo[2,1-b][1,3,4]thiadiazole
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC24H27FN6O3S2
Molar mass530.64 g·mol−1
3D model (JSmol)
  • CCC1=CN=C(N=C1)N2CCC(CC2)[C@H](C)OC3=NN4C=C(N=C4S3)C5=C(C=C(C=C5)S(=O)(=O)C)F
  • InChI=1S/C24H27FN6O3S2/c1-4-16-12-26-22(27-13-16)30-9-7-17(8-10-30)15(2)34-24-29-31-14-21(28-23(31)35-24)19-6-5-18(11-20(19)25)36(3,32)33/h5-6,11-15,17H,4,7-10H2,1-3H3/t15-/m0/s1
  • Key:UUMBXZTUKTTYMG-HNNXBMFYSA-N

Deziglipel (INNTooltip International Nonproprietary Name; developmental code name MKP10241) is a GPR119 agonist with antihyperglycemic actions which is under development for the treatment of obesity and type 2 diabetes. It is taken orally. The drug has been found to reduce glucose levels and HbA1c in rodents, including in models of diabetes. In addition, it markedly reduced feed intake and body weight in such rodents. The drug also reduced metabolic dysfunction–associated steatotic liver disease (MASLD) in a rodent model of the disease. Deziglipel is under development by Mankind Pharma. As of November 2025, it is in phase 2 clinical trials for both obesity and type 2 diabetes.

See also

References

  1. 1 2 3 4 5 "MKP 10241". adisinsight.springer.com. Retrieved 28 October 2026.
  2. 1 2 3 4 Rai SK, Patil RI, Ali S, Kumar R, Khan MI, Panwar A, et al. (November 2025). "Discovery of MKP10241, a Novel Small Molecule Targeting the GPR119/Incretin Axis to Treat Metabolic Disorders". Journal of Medicinal Chemistry. 68 (22): 23781–23800. doi:10.1021/acs.jmedchem.5c00540. PMID 41054342.